Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 7/20 | 0.92 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.80 |
| ▸ | NSD2 | O96028 | 1/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.79 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.79 |
| ▸ | BID | P55957 | 1/20 | 0.79 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.79 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.79 |
| ▸ | ASPH | Q12797 | 1/20 | 0.79 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.79 |
| ▸ | BAD | Q92934 | 1/20 | 0.79 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.79 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1702539 | 0.96 | BCL2 (1.00) | BCL2BCL2L1NSD2ADORA3CYP2C9 | |
| SCHEMBL30468002 | 0.96 | BCL2 (1.00) | BCL2BCL2L1NSD2ADORA3CYP2C9 | |
| SCHEMBL17250053 | 0.92 | BCL2 (0.92) | BCL2BCL2L1NSD2ADORA3CYP2C9 | |
| SCHEMBL1957486 | 0.92 | BCL2 (0.93) | BCL2 | |
| SCHEMBL19419621 | 0.91 | BCL2 (0.92) | BCL2 | |
| SCHEMBL1955090 | 0.91 | BCL2 (0.92) | BCL2 | |
| SCHEMBL1954728 | 0.91 | BCL2 (0.92) | BCL2 | |
| SCHEMBL1957657 | 0.91 | BCL2 (0.92) | BCL2 | |
| SCHEMBL2483608 | 0.91 | BCL2 (0.92) | BCL2 | |
| SCHEMBL1958638 | 0.91 | BCL2 (0.92) | BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180055847-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180055847-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL3 | BCL2 1/4885BCL2L1 6/4885NSD2 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.